These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 741072)

  • 1. [Contribution to the biochemical treatment of the Parkinson's disease (author's transl)].
    Calatayud Maldonado V
    Rev Esp Otoneurooftalmol Neurocir; 1978; 36(204):33-41. PubMed ID: 741072
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J; Avila C; Bazán E; García E; Gervás J; Maseda C; Mena M; Muradas V; Ramos JA
    Med Clin (Barc); 1982 Apr; 78(7):259-64. PubMed ID: 7087591
    [No Abstract]   [Full Text] [Related]  

  • 3. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of fusaric acid calcium on catecholamine metabolism and its clinical effects on essential hypertension].
    Ozawa M; Nakajima Y; Suzuki K; Sato T; Takahashi E
    Horumon To Rinsho; 1976 Jan; 24(1):79-86. PubMed ID: 942902
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of fusaric acid in Parkinson's disease.
    Herskovits E; Figueroa Gacitua E
    Medicina (B Aires); 1973; 33(1):51-8. PubMed ID: 4573120
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mortality in Parkinson's disease and its modification by levodopa (author's transl)].
    Schneider E; Fischer PA; Jacobi P; Kolb R
    Fortschr Neurol Psychiatr; 1981 May; 49(5):187-92. PubMed ID: 7239405
    [No Abstract]   [Full Text] [Related]  

  • 7. [The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
    Campanella G; Pennetta R
    Riv Patol Nerv Ment; 1974 Oct; 95(5):673-5. PubMed ID: 4470267
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of pheochromocytoma with fusaric acid].
    Shimpo S; Sakata K; Kawashimo K; Kanagi R; Omori Y
    Horumon To Rinsho; 1976 Jun; 24(6):571-6. PubMed ID: 986906
    [No Abstract]   [Full Text] [Related]  

  • 11. [Proceedings: Case of pheochromocytoma].
    Kawahara H; Kuzutani F; Mizuno S
    Jpn Circ J; 1975 Jul; 39(7):871. PubMed ID: 1160060
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of craving and withdrawal in humans addicted to narcotics or amphetamines by administration of alpha-methyl-para-tyrosine (AMPT) and 5-butylpicolinic acid (fusaric acid) treatment of narcotic and amphetamine addiction in humans: preliminary report.
    Pozuels J
    Cleve Clin Q; 1976; 43(2):89-94. PubMed ID: 1277534
    [No Abstract]   [Full Text] [Related]  

  • 14. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased dopamine in the retinas of patients with Parkinson's disease.
    Harnois C; Di Paolo T
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
    Indo T
    Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
    [No Abstract]   [Full Text] [Related]  

  • 18. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 19. Tryptophan/nicotinic acid pathway during levodopa treatment of Parkinsonism.
    Cozzolino G; Campriani S; Campanelli C
    Acta Vitaminol Enzymol; 1975; 29(1-6):202-5. PubMed ID: 1244093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Two cases of Parkinson's disease with diphasic dyskinesia, seen during levodopa treatment (author's transl)].
    Mano Y; Ando K; Muramoto O; Riku S
    Rinsho Shinkeigaku; 1982 Mar; 22(3):209-15. PubMed ID: 7105593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.